The blockade of immune checkpoints in cancer immunotherapy

@article{Pardoll2012TheBO,
  title={The blockade of immune checkpoints in cancer immunotherapy},
  author={Drew M. Pardoll},
  journal={Nature Reviews Cancer},
  year={2012},
  volume={12},
  pages={252-264}
}
  • D. Pardoll
  • Published 22 March 2012
  • Biology, Medicine
  • Nature Reviews Cancer
Among the most promising approaches to activating therapeutic antitumour immunity is the blockade of immune checkpoints. Immune checkpoints refer to a plethora of inhibitory pathways hardwired into the immune system that are crucial for maintaining self-tolerance and modulating the duration and amplitude of physiological immune responses in peripheral tissues in order to minimize collateral tissue damage. It is now clear that tumours co-opt certain immune-checkpoint pathways as a major… 

Immune checkpoint blockade opens a new way to cancer immunotherapy

TLDR
An overview of the immune checkpoint pathways, including CTLA‐4, PD‐1, lymphocyte activation gene 3, T‐cell immunoglobulin and mucin domain 3, B7‐H3, and diacylglycerol kinase α and implications of their inhibition in the cancer therapy are provided.

Developing Cancer Immunotherapies by the manipulation of Immune Checkpoints

TLDR
Preliminary clinical findings with blockers of additional immune checkpoint proteins, such as Programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumor immunity with the potential to produce durable clinical responses.

CANCER IMMUNOTHERAPY BASED ON THE BLOCKADE OF IMMUNE CHECKPOINTS

TLDR
The blockade of inhibitory signal that is transduced in immune checkpoints leading to the reactivation of antitumor immune response is a promising method of tumor immunotherapy.

Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies

TLDR
Understanding the different mechanisms of action, safety profiles, and response patterns associated with inhibition of the CTLA-4 and PD-1 pathways may improve patient management and provide a rationale for combination therapy with different inhibitors.

Checkpoint Inhibitors and Their Application in Breast Cancer

TLDR
The evidence supporting the implementation of checkpoint inhibition in breast cancer is summarized by reviewing in detail data on PD-L1 expression and its regulation and opportunities to boost anti-tumor immunity with checkpoint inhibitor-based immunotherapies alone and in combination with other treatment options will be discussed.

Next generation of immune checkpoint therapy in cancer: new developments and challenges

TLDR
A comprehensive review of immune checkpoint pathways involved in cancer immunotherapy is provided, and their mechanisms and the therapeutic interventions currently under investigation in phase I/II clinical trials are discussed.

Immune Checkpoint inhibitors: An introduction to the next‐generation cancer immunotherapy

TLDR
The scientific overview of cancer immunotherapy, mechanisms of the inhibitors, clinical pharmacology considerations, advances in combination therapies, and challenges in drug development are discussed.

Present and future of immune checkpoint blockade: Monotherapy to adjuvant approaches

TLDR
The development of immune checkpoint blockade as a potential future immunotherapy has led to increasing interest in combining treatment modalities, and combination checkpoint blockade with bacterial vaccine vectors have produced increased effector immune responses in pre-clinical models.

Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity

TLDR
The recent progressions in the research of the immune checkpoint molecules and the application of their blocking antibodies in cancer treatment are reviewed, and the cardiac toxicity induced by the therapy and the strategy to monitor, manage this adverse event when it occurs is discussed.
...

References

SHOWING 1-10 OF 135 REFERENCES

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.

TLDR
A strong synergy between the PD-1 and LAG-3 inhibitory pathways in tolerance to both self and tumor antigens is defined and it is argued strongly that dual blockade of these molecules represents a promising combinatorial strategy for cancer.

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

TLDR
It is concluded that the combination of direct enhancement of Teff cell function and concomitant inhibition of T reg cell activity through blockade of CTLA-4 on both cell types is essential for mediating the full therapeutic effects of anti–CTLA- 4 antibodies during cancer immunotherapy.

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

  • F. HodiM. Mihm G. Dranoff
  • Biology, Medicine
    Proceedings of the National Academy of Sciences of the United States of America
  • 2003
TLDR
Findings suggest that CTLA-4 antibody blockade increases tumor immunity in some previously vaccinated cancer patients.

Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors.

TLDR
This work reports an extensive characterization of the therapeutic activity and mechanism of action of an anti-mouse TIM3 mAb against experimental and carcinogen-induced tumors, and for the first time defines the mechanism of antitumor action of anti-TIM3 requiring IFN-γ producing CD8(+) T cells and CD4(+) T cells correlating with therapeutic success.

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

  • G. PhanJ. Yang S. Rosenberg
  • Biology, Medicine
    Proceedings of the National Academy of Sciences of the United States of America
  • 2003
TLDR
This study establishes CTLA-4 as an important molecule regulating tolerance to “self” antigens in humans and suggests a role for CTla-4 blockade in breaking tolerance to human cancer antIGens for cancer immunotherapy.

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

TLDR
It is found that T cell immunoglobulin mucin (Tim) 3 is expressed on CD8+ tumor-infiltrating lymphocytes (TILs) in mice bearing solid tumors and combined targeting of the Tim-3 and PD-1 pathways is more effective in controlling tumor growth than targeting either pathway alone.

Enhancing SIV-Specific Immunity In Vivo by PD-1 Blockade

Chronic immunodeficiency virus infections are characterized by dysfunctional cellular and humoral antiviral immune responses. As such, immune modulatory therapies that enhance and/or restore the

PD-1 and its ligands in tolerance and immunity.

TLDR
Current understanding of the immunoregulatory functions of PD-1 and its ligands and their therapeutic potential are discussed and an inhibitory bidirectional interaction between PD-L1 and B7-1 is discovered, revealing new ways the B7:CD28 family regulates T cell activation and tolerance.

Clinical development of the anti-CTLA-4 antibody tremelimumab.

  • A. Ribas
  • Biology, Medicine
    Seminars in oncology
  • 2010
TLDR
The lack of survival advantage in the early analysis of a phase III clinical trial comparing tremelimumab with standard chemotherapy for metastatic melanoma highlights the importance of gaining a better understanding of how this antibody modulates the human immune system and how to better select patients for this mode of therapy.

Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

TLDR
It is shown that a fraction of blood monocyte-derived myeloid dendritic cells (MDCs) express B7-H1, a member of the B7 family, on the cell surface, which could be further upregulated by tumor environmental factors.
...